Overview
Nona Biosciences provides integrated antibody discovery, engineering, and development services using proprietary fully human transgenic mice platforms like Harbour Mice and HCAbs. Capabilities include bispecific/multispecific engineering, mRNA-LNP delivery, phage/yeast display, and AI-enhanced platforms such as Hu-mAtrIx for optimized lead selection. The company supports projects from antigen preparation through IND-enabling studies and early clinical development.
Frequently asked questions
- What antibody discovery platforms does Nona Biosciences offer?
- Nona offers fully human antibody discovery using HCAb Harbour Mice for single-domain VH antibodies, phage display, yeast display, and AI-powered Hu-mAtrIx for binding prediction and developability assessment.
- What engineering capabilities are available for bispecific antibodies?
- Nona provides bispecific and multispecific engineering with HCAb platforms, modular screening of constructs, antigen preparation, and developability assessments to de-risk development.
- Does Nona support clinical development stages?
- Yes, Nona has expanded to integrated discovery-to-clinical capabilities, including CMC development, toxicology, IND-enabling activities, and support for early clinical development and Investigator-Initiated Trials.